NEWS

Novel Diabetes Treatment May Increase Risk for Cancer
August 10, 2011

Chemo Plus Radiation Beats Surgery in Muscle Invasive Bladder Cancer
Oncology NEWS International, December 23, 2010

Gemcitabine Sensitizes Invasive Bladder Tumors to Radiation
Oncology NEWS International, May 17, 2010

Point-of-Care Test for Recurrent Bladder Cancer Available
ONCOLOGY, March 16, 2009

Broccoli Sprouts Extract Might Lower Bladder Cancer Risk
Oncology NEWS International, January 1, 2008

JOB LISTINGS

Post a job

PRACTICE GUIDELINES

Guide to Clinical Preventive Services, 2010-2011: Section 2

www.ahrq.gov -

National Guideline Clearinghouse | Guidelines on TaT1 (non-muscle invasive) bladder cancer.

www.guidelines.gov -

National Guideline Clearinghouse | Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta,T1, and Tis): 2007 update.

www.guidelines.gov -

CONNECT WITH US

	Become a fan on Facebook
	Add us on Google Plus
	Follow us on Twitter
	Sign up for our Newsletters
	Subscribe to our RSS Feed

Bladder Cancer

Management of Locally Invasive Bladder Cancer

REVIEW ARTICLE
Rian J. Dickstein, Ashish M. Kamat, MD; ONCOLOGY Vol. 25 No. 14
Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
• Challenges in the Modern Treatment of Muscle-Invasive Bladder Cancer
• Bladder Cancer Treatment: Optimize, Don't Compromise
Solitary Extramedullary Plasmacytoma of the Bladder

CLINICAL QUANDARIES
Waseem Khaliq, Ikechukwu Uzoaru, et al; ONCOLOGY Vol. 24 No. 9
Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
• Solitary Extramedullary Plasmacytomas vs Multiple Myeloma
• Rare Bladder Tumors: Caveat Emptor
A Man With Changes in the Urinary Bladder

SECOND OPINION
Thomas W. Flaig, Francisco G. La Rosa, et al; ONCOLOGY Vol. 23 No. 2
The patient is a 39-year-old man who presents with pelvic lymphadenopathy. He has a history of ureteral reflux disease, recurrent nephrolithiasis, right nephrectomy, ileal loop diversion of the left ureter, and radical cystectomy for “bladder cancer,” which he underwent 3 years ago. The lymphadenopathy was discovered incidentally during recent imaging.

REVIEW ARTICLES

Contemporary Management of Locally Invasive Bladder Cancer
Rian J. Dickstein, MD¹, Ashish M. Kamat, MD¹ , December 31, 2011

Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
• Challenges in the Modern Treatment of Muscle-Invasive Bladder Cancer
• Bladder Cancer Treatment: Optimize, Don't Compromise

Bladder Cancer: Imperatives for Personalized Medicine
Ashish M. Kamat, MD¹, Paul Mathew, MD² , September 12, 2011

This article reviews existing management paradigms and challenges in bladder cancer treatment today. Also a discussion on personalized medicine, molecular and cellular pathogenesis, and molecular therapies.
• Bladder Cancer: A Condition Worthy of Clinical Investigation
• Bladder Cancer: Time for a Rethink?

Hyperthermia as a Treatment for Bladder Cancer
Edward N. Rampersaud, MD¹, Zeljko Vujaskovic, MD, PhD¹, Brant A. Inman, MD, FRCS(C)¹ , November 5, 2010

This review highlights the biology of therapeutic fever-range hyperthermia, and summarizes the data supporting the role of hyperthermia in the management of bladder cancer.
• Intravesical Hyperthermia and Chemotherapy for Bladder Cancer
• Hyperthermia and Intravesical Therapy: Emerging One-Two Punch?

Solitary Extramedullary Plasmacytoma of the Bladder
Waseem Khaliq, MD, MPH¹, Ikechukwu Uzoaru, MD², Ronald P. Konchanin, MD³, Ronald A. Sapiente, MD⁴, James R. Egner, MD⁵ , August 23, 2010

Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
• Rare Bladder Tumors: Caveat Emptor
• Solitary Extramedullary and Bone Plasmacytomas versus Multiple Myeloma with Extramedullary Manifestation

Recurrent Urothelial Carcinoma With Pulmonary Metastasis
Vassilis J. Siomos, MD¹, Francisco G. La Rosa, MD², Thomas W. Flaig, MD³, Kimi L. Kondo, DO⁴, J.D. Mitchell, MD⁵, Shandra Wilson, MD⁶, Al B. Barqawi, MD, FRCS⁷ , December 17, 2009

A 56-year-old woman was referred to our institution for a left nephroureterectomy after the diagnoses of a nonfunctioning left kidney and noninvasive papillary urothelial carcinoma of the distal left ureter (Ta grade 1). CT scan of the abdomen and pelvis demonstrated a large bladder tumor with pan-urothelial extension.

JOURNAL SCAN

British Journal of Cancer - Abstract of article: Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer

www.nature.com - 1/12/12

The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independenc

MMP-2 and MMP-9 in lymph-node-positive bladder cancer -- Seiler et al. 64 (12): 1078 -- Journal of Clinical Pathology

jcp.bmj.com - 12/1/11

J Clin Pathol. 2011; 64: 1078-1082 doi: 10.1136/jclinpath-2011-200153. Original article. MMP-2 and MMP-9 in lymph-node-positive bladder cancer. ... Their significance in urothelial cancer of the bladder ( UCB) is unclear.

Occupational exposure to crack detection dye penetrants and the potential for bladder cancer -- Noon et al. -- Occupational and Environmental Medicine

oem.bmj.com - 11/7/11

Occup Environ Med. doi: 10.1136/oemed-2011-100379. PostScript. Letter. Occupational exposure to crack detection dye penetrants and the potential for bladder cancer. ... We have been interested in occupational bladder cancer ( urothelial cell carcinoma (

WJSO | Comments | The association of fish consumption with bladder cancer risk: a meta-analysis

www.wjso.com - 9/19/11

The association between fish consumption and risk of bladder cancer has not been established yet. The results from epidemiological studies are inconsistent.|The association between fish consumption and risk of bladder cancer has not been established yet. The results from epidemiological studies are inconsistent.

Oncogene - Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor stat

www.nature.com - 1/9/12

Oncogene is one of the worlds leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.

MEDLINE

Imaging of bladder cancer: update on current approaches for diagnosis.

pubmed.gov - 10/10/11

Imaging plays a mainstay role in evaluation of patients with bladder cancer, especially for diagnosis, local and distant staging and treatment follow up. In this article, we aim to review and to update conventional and functional imaging methods used in clinical management of bladder cancer.

The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells.

pubmed.gov - 10/1/11

NSBP1 is a recently identified member of the HMGN protein family which binds to nucleosomes and regulates gene transcription through chromatin remodeling. In this study, we aimed to investigate the potential role of NSBP1 in human bladder cancer. We examined NSBP1 expression in 114 surgically removed bladder cancer specimens as well as 11 human bladder cell lines by immunohistochemistry and Western blot analysis, and found that NSBP1 level was correlated with the increased tumor grade and pathologic stage, and lymph node metastasis. RNAi-mediated knockdown of NSBP1 in EJ cells, a bladder cancer cell line that overexpressed NSBP1, resulted in moderate decrease of cell viability, moderate blockage of cell cycle at G2/M phase, and decreased cyclin B1 expression, but had no effects on apoptosis. Moreover, NSBP1 knockdown led to reduced activity of MMP-9 but not MMP-2. Taken together, these results suggest that NSBP1 promotes the viability of bladder cancer cells through increased cell

Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.

pubmed.gov - 10/1/11

Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer?

pubmed.gov - 10/1/11

OBJECTIVE To determine how the presence of MP on T1 biopsy specimens affects the outcome of patients undergoing RC as compared to when no MP is identified in the TURBT specimen.| Patients were retrospectively identified from the Columbia University Urologic Oncology Database. From January 1986 to October 2009, 114 patients diagnosed with cT1N0M0 bladder cancer who underwent RC within 4 months of their last biopsy were identified. Patients were stratified based on the presence of MP on T1 biopsy, and upstaging was defined as any tumor T2 or greater, N+, or M+ at the time of radical cystectomy. The rate of upstaging was assessed using univariate and multivariate regression models; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns.| Of the 114 patients evaluated in this study, 24 (20.2%) did not have MP on their T1 biopsy before RC. The rate of upstaging (>=pT2) stratified by the presence of MP on

[Peculiarities of urinary bladder cancer tumor cells apoptosis response on neoadjuvant chemotherapy].

pubmed.gov - 9/28/11

Induced apoptosis in urinary bladder cancer tumor cells of patients was studied using TUNEL reaction. It was shown that increase in induced apoptosis value had a definite correlation between corresponding features of tumor reaction as a response on Gemcitabine-Cisplatin neoadjuvant chemotherapy application. It was found that evaluation of induced apoptosis in urinary bladder cancer tumor cells using TUNEL method allows forecasting the effectiveness of chemotherapy on the cellular level in patients with this type of cancer.

CLINICAL TRIALS

Biobank Bladder Carcinoma: Storing Blood and Protein of Patients With Bladder Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Cone Beam CT Scanning in Lung and Bladder Cancer. - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Quality of Life in Patients With Bladder Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

TOPIC INDEX

Bladder Cancer

Management of Locally Invasive Bladder Cancer

Solitary Extramedullary Plasmacytoma of the Bladder

A Man With Changes in the Urinary Bladder